Startups
Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects.
ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure.
The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources.
Critical Diagnostics is headquartered in San Diego, California.
Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above.
ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure.
The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources.
Critical Diagnostics is headquartered in San Diego, California.
Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above.
Overview
Location
United States, California, San Diego
Employees
11-50
Total raised
$8.5M
Founded date
2004
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 3, 2018 | Critical Diagnostics Raises $8.5M For Cardiac Assays | San Diego-based Critical Diagnostics has raised $8.5M in a funding round, the company said on Wednesday. The company develops cardiac biomarker tests used by physicians to assess heart failure patients. Names of the specific investors in th... |
| Mar 28, 2013 | Cardiac biomarker firm get $2.6M to bring ST2 test for early signs of heart failure to labs | In its research, Critical Care has demonstrated that ST2 provides unique information to the cardiac biomarkers commonly used today and that it is useful predictor of adverse patient outcomes in cardiovascular disease. The company positions ... |
| Cardiac biomarker firm get $2.6M to bring ST2 test for early signs of heart failure to labs | Cardiac diagnostics firm Critical Care Diagnostics Inc. has landed some new capital as it works with clinical laboratories to make its cardiac biomarker assay, ST2, available to physicians. The company announced a private placement last mon... |
Reviews 0
FAQ about Critical Diagnostics
When was Critical Diagnostics founded?
Critical Diagnostics was founded in 2004.
How much funding has Critical Diagnostics raised?
Critical Diagnostics has raised $8.5M in total across 1 funding round.
What has the press written about Critical Diagnostics?
Parsers VC has collected 4 articles mentioning Critical Diagnostics, among them “Critical Diagnostics Raises $8.5M For Cardiac Assays” (Jan 3, 2018) and “Cardiac biomarker firm get $2.6M to bring ST2 test for early signs of heart failure to labs” (Mar 28, 2013).
Is Critical Diagnostics still active?
Yes, Critical Diagnostics is active; its latest activity on Parsers VC dates from Jan 3, 2018.